Denali Therapeutics (DNLI) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

Denali Therapeutics (DNLI) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Denali Therapeutics

· DNLI

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

3.326 B

-0.67%

General

Market Cap: $3.33B
Enterprise Value: $3.11B
Shares Outstanding: —
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: -61.04%
Operating Margin: -15058.19%
Net Profit Margin: -14191.20%
FCF Margin: -12138.10%
ROA: -44.17%
ROE: -55.27%
ROIC: -50.82%
Current Ratio: 8.37
Debt-to-Equity: 0.03
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: —
P/S: 910.25
P/FCF: —
P/B: 3.93
EV/EBITDA: -6.25

Growth

Rev 1Y: —
Rev 1Y Fwd Est: —
Rev 3Y (CAGR): —
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —
EPS 5Y (CAGR): —

Income Statement (TTM)

Revenue: $3.6M
Gross Margin: -61.04%
Operating Expenses: $540.5M
Operating Income: -$542.7M
Net Profit: -$511.45M

Balance Sheet

EPS 10Y (CAGR)

—

Cash and Equivalents: $201.53M
Working Capital: $663.84M
Total Assets: $1.16B
Net Debt: -$174.03M
Total Liabilities: $322.78M
Total Equity: $835.18M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$434.04M
Cash Flow from Investing: $68.98M
Cash Flow from Financing: $425.38M
Free Cash Flow: -$437.46M
Capital Expenditures: $3.42M